Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S. Neelapu, William Y. Go, Ira Braunschweig et al.|New England Journal of Medicine|2017Cited by 6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialFrederick L. Locke, Sattva S. Neelapu, Armin Ghobadi et al.|The Lancet Oncology|2018Cited by 2.3k
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1Sattva S. Neelapu, William Y. Go, Frederick L. Locke et al.|Blood|2016Cited by 51